Frontlight ResearchEarly access
CompletedPhase 1
A study of the safety, tolerability, pharmacokinetics and preliminary efficacy of TNV108 in healthy adults and patients with diabetic peripheral neuropathy
Key facts
- Who runs it
- Tenvie Therapeutics Inc.
- Where
- Netherlands1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 108 people enrolled
- Started
- 2 Mar 2026
- Ended
- 30 Oct 2026
- Type of study
- Interventional
- Record updated
- 24 February 2026
Who can take part
- Age
- 18 years to 64 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 24 February 2026